Optimal length of triple therapy for H pylori eradication in a population with high prevalence of infection in Chile

Table 1 Baseline characteristics of patients n (%)

	OAC7 (n = 69)	OAC14 (n = 62)
Age (yr)	47.5 ± 16	45 ± 15
Male	27 (39.1)	18 (29)
Smokers	14 (20.3)	21 (33.9)
Previous antibiotic exposure
Betalactamics	56 (81.2)	51 (82.3)
Clarithromycin	13 (18.8)	18 (29)
Metronidazol	13 (18.8)	12 (19.4)
Tetracyclines	32 (46.4)	26 (41.9)
Endoscopic diagnosis
Ulcer disease	14 (20.3)	24 (38.7)
Non-ulcer disease	44 (63.8)	30 (48.4)
Normal	11 (15.9)	8 (12.9)

Table 2 Eradication rate after treatment and subgroup analyses n (%)

Eradication rate according to:	OAC7(n = 69)	OAC14(n = 62)	P
Length of treatment	54 (78.3)	53 (85.5)	0.37
Smoking status
Smoker	8 (57.1)	17 (81)	0.15
Non smoker	46 (83.6)	36 (87.8)	0.88
Endoscopic diagnosis
Ulcer disease	12 (85.7)	21 (87.5)	1.0
Non-ulcer disease	35 (79.5)	25 (83.3)	0.77
Normal	7 (63.6)	7 (87.5)	0.34
Previous antibiotic exposure
Betalactamics	46 (82.1)	43 (84.3)	0.8
Clarithromycin	10 (76.9)	16 (88.9)	0.63
Metronidazol	9 (69.2)	10 (83.3)	0.64
Tetracycline	25 (78.1)	20 (76.9)	1.0

Table 3 Adverse events during treatment n (%)

	OAC7(n = 69)	OAC14(n = 62)	Total(n = 131)
Abdominal pain	10 (14.5)	8 (12.9)	18 (13.7)
Nausea	7 (10.1)	11 (17.7)	18 (13.7)
Diarrhea	9 (13.0)	5 (8)	14 (10.7)
Taste disturbance	2 (2.9)	7 (11.3)	9 (6.9)
Headache	2 (2.9)	5 (8.1)	7 (5.3)
Vomiting	1 (1.58)	2 (3.2)	3 (2.3)
Loss of appetite	2 (2.9)	1 (1.6)	3 (2.3)
Rash	0	2 (3.2)	2 (1.5)
Discolored faeces	1 (1.4)	1 (1.6)	2 (1.5)
Tongue discoloration	1 (1.4)	0	1 (0.76)
Total	20 (29)	23 (37)	43 (33)